2-丁基己酰胺 | 52922-49-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 2-丁基己酰胺
• 英文名称: 2-butyl-hexanoic acid amide
• 英文别名: 2-Butyl-hexansaeure-amid；Nonan-carbonsaeure-(5)-amid；2-Butyl-capronsaeure-amid；Dibutylessigsaeure-amid；Dibutylacetamid；2-Butylhexanamide
• CAS: 52922-49-3
• 化学式: C₁₀H₂₁NO
• 分子量: 171.283
• InChiKey: XPEOTZMXIWGSAB-UHFFFAOYSA-N

物化性质

• 沸点：
  305.0±10.0 °C(Predicted)
• 密度：
  0.879±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  12
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2-丁基己酰胺 在 甲醇 、 溴 、 sodium methylate 作用下， 生成 (1-butyl-pentyl)-carbamic acid methyl ester
  参考文献：
  名称：

  Bezzi et al., Farmaco, Edizione Scientifica, 1950, vol. 5, p. 260,264

  摘要：

  DOI：
• 作为产物：
  描述：

  二丁基乙酸 在 氯化亚砜 作用下， 生成 2-丁基己酰胺
  参考文献：
  名称：

  Dolique, Annales de Chimie (Cachan, France), 1931, vol. <10> 15, p. 425,505, 506

  摘要：

  DOI：

文献信息

• [EN] PROCESS OF PREPARING GLYCOLALDEHYDE<br/>[FR] PROCEDE DE PREPARATION DE GLYCOLALDEHYDE
  申请人：SHELL INT RESEARCH

  公开号：WO2005058788A1

  公开（公告）日：2005-06-30

  The invention provides a process of preparing glycolaldehyde by reacting formaldehyde with hydrogen and carbon monoxide in the presence of a catalyst composition which is based on, a) a source of rhodium, and b) a ligand of general formula R1P-R2(I), wherein R1 is a bivalent radical that together with the phosphorous atom to which it is attached is an optionally substituted 2-phospha-tricyclo[3.3.1.13,7}]-decyl group, wherein from 1 to 5 of the carbon atoms has been replaced by a heteroatom, and wherein R2 is a monovalent radical which is an optionally substituted hydrocarbyl group having from 1 to 40 carbon atoms; a catalyst composition of use in said process; and a process of preparing ethylene glycol from the glycolaldehyde thus prepared.

  该发明提供了一种制备甘醛的方法，通过在催化剂组合物的存在下，将甲醛与氢气和一氧化碳反应，所述催化剂组合物基于a)铑的来源，和b)一般式R1P-R2(I)的配体，其中R1是一个二价基团，与其连接的磷原子一起是一个可选择替代的2-磷杂-三环[3.3.1.13,7}]-癸基团，其中1到5个碳原子已被杂原子取代，而R2是一个单价基团，是一个可选择替代的碳氢基团，含有1到40个碳原子；用于该方法的催化剂组合物；以及从制备的甘醛制备乙二醇的方法。
• 1H-Quinolin-4-one compounds, with affinity for the GABA receptor, processes, uses and compositions
  申请人：FERRER INTERNACIONAL, S.A.

  公开号：EP1886996A1

  公开（公告）日：2008-02-13

  The invention provides new 1 H-quinolin-4-one compounds of formula (I), wherein R1, R2, R3, R4 and R5 have different meanings, and pharmaceutically acceptable salts and hydrates thereof. Compounds of formula (I) are useful for treating or preventing diseases associated with GABAA receptors modulation, anxiety, epilepsy, sleep disorders including insomnia, and for inducing sedation-hypnosis, anesthesia, sleep and muscle relaxation. The invention also provides synthetic procedures for preparing said compounds.

  该发明提供了新的1H-喹啉-4-酮化合物的化学式(I)，其中R1、R2、R3、R4和R5具有不同的含义，以及其药学上可接受的盐和水合物。化合物的化学式(I)对于治疗或预防与GABAA受体调节、焦虑、癫痫、包括失眠在内的睡眠障碍以及诱导镇静-催眠、麻醉、睡眠和肌肉松弛相关的疾病是有用的。该发明还提供了制备这些化合物的合成方法。
• [EN] NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND &bgr;-LACTAMASE INHIBITORS<br/>[FR] NOUVEAUX COMPOSÉS HÉTÉROCYCLIQUES ET LEUR UTILISATION EN TANT QU'AGENTS ANTIBACTÉRIENS ET INHIBITEURS DE &Bgr;-LACTAMASE
  申请人：NAEJA PHARMACEUTICAL INC

  公开号：WO2014141132A1

  公开（公告）日：2014-09-18

  The present invention relates to new heterocyclic compounds, their preparation and their use as β−lactamase inhibitors in combination with one or more antibiotics for the treatment of infections caused by β−lactamase-producing pathogenic bacteria.

  本发明涉及新的杂环化合物，其制备以及它们作为β-内酰胺酶抑制剂与一种或多种抗生素结合，用于治疗由β-内酰胺酶产生的致病菌引起的感染。
• Lercanidipine Hydrochloride Polymorphs and an Improved Process for Preparation of 1,1,N-Trimethyl-N-(3,3-Diphenylpropyl)-2-Aminoethyl Acetoacetate
  申请人：Dixit Girish

  公开号：US20100104649A1

  公开（公告）日：2010-04-29

  Disclosed herein is an improved, commercially viable and industrially advantageous process for the preparation of substantially pure Lercanidipine intermediate, 1,1,N-trimethyl-N-(3,3-diphenylpropyl)-2-aminoethyl acetoacetate. The intermediate is useful for preparing Lercanidipine, or a pharmaceutically acceptable salt thereof, in high yield and purity. The present invention further provides a novel crystalline form of Lercanidipine hydrochloride and a process for its preparation. The present invention also provides a process for the preparation of amorphous form of Lercanidipine hydrochloride.

  本文公开了一种改进的、商业可行的和工业上有利的制备基本纯Lercanidipine中间体1,1,N-三甲基-N-(3,3-二苯基丙基)-2-氨基乙酰乙酸酯的方法。该中间体可用于高收率和高纯度地制备Lercanidipine或其药学上可接受的盐。本发明还提供了一种新的晶体形式的Lercanidipine盐酸盐及其制备方法。本发明还提供了一种制备Lercanidipine盐酸盐无定形形式的方法。
• Process for preparing Michael addition products and for converting them to ibuprofen, an anti-inflammatory compound
  申请人：THE UPJOHN COMPANY

  公开号：EP0022440A1

  公开（公告）日：1981-01-21

  A Michael condensation product is prepared from α-acetyl-α'-methylsuccinate esters and isobutyl vinyl ketone using a dipolar, aprotic liquid solvent, preferably a dialkyl sulfoxide, a dialkylformamide or a dialkylacetamide, and potassium tert-butoxide. The Michael product of this process can be converted to ibuprofen, an anti-inflammatory drug.

  迈克尔缩合产物是由α-乙酰基-α'-甲基琥珀酸酯和异丁基乙烯基甲酮通过二极性、非正交液体溶剂（最好是二烷基亚砜、二烷基甲酰胺或二烷基乙酰胺）和叔丁醇钾制备而成。该工艺的迈克尔产物可转化为布洛芬，一种消炎药。